TEST BANK
FOR
ADVANCED PHARMACOLOGY FOR PRESCRIBERS,
1ST EDITION BY LUU, KAYINGO, AND HASS
COMPLETE CHAPTERS 1-36
MCQs WITH RATIONALIZED ANSWERS
,TABLE OF CONTENTS
PART I: FOUNDATIONS OF PHARMACOLOGY AND PRESCRIBING
CHAPTER 1: AN INTRODUCTION TO EVIDENCE-BASED CLINICAL
PRACTICE GUIDELINES
CHAPTER 2: PHARMACOKINETICS
CHAPTER 3: PHARMACODYNAMICS
CHAPTER 4: PHARMACOGENETICS AND PHARMACOGENOMICS
CHAPTER 5: PHARMACOLOGY ACROSS THE LIFE SPAN
CHAPTER 6: DRUG-THERAPY PRESCRIBING IN SPECIAL POPULATIONS
CHAPTER 7: DRUG DEVELOPMENT AND APPROVAL
CHAPTER 8: BASICS OF PRESCRIPTION WRITING
CHAPTER 9: RESPONSIBLE CONTROLLED-SUBSTANCE PRESCRIBING
CHAPTER 10: ANTIBIOTIC STEWARDSHIP
CHAPTER 11: APPLIED CALCULATIONS FOR PRESCRIBING
CHAPTER 12: PROMOTING ADHERENCE WITH PHARMACOTHERAPY
PART II: SYSTEM-SPECIFIC AND PATIENT-FOCUSED PRESCRIBING
CHAPTER 13: PHARMACOTHERAPY FOR EAR, NOSE, ORAL, AND THROAT
CONDITIONS
CHAPTER 14: PHARMACOTHERAPY FOR EYE CONDITIONS
CHAPTER 15: PHARMACOTHERAPY FOR SKIN CONDITIONS
CHAPTER 16: PHARMACOTHERAPY FOR NEUROLOGIC CONDITIONS
CHAPTER 17: PHARMACOTHERAPY FOR CARDIOVASCULAR CONDITIONS
, CHAPTER 18: PHARMACOTHERAPY FOR RESPIRATORY CONDITIONS
CHAPTER 19: PHARMACOTHERAPY FOR GASTROINTESTINAL CONDITIONS
CHAPTER 20: PHARMACOTHERAPY FOR GENITOURINARY CONDITIONS
CHAPTER 21: PHARMACOTHERAPY FOR RENAL, ACID-BASE, AND
FLUID/ELECTROLYTE DISORDERS
CHAPTER 22: PHARMACOTHERAPY FOR MUSCULOSKELETAL AND
RHEUMATOLOGIC CONDITIONS
CHAPTER 23: THERAPEUTIC APPLICATIONS OF IMMUNOLOGY AND VACCINES
CHAPTER 24: PHARMACOTHERAPY FOR ENDOCRINE DISORDERS
CHAPTER 25: PHARMACOTHERAPY FOR HEMATOLOGIC DISORDERS
CHAPTER 26: HEMATOLOGY/ONCOLOGY AND SUPPORTIVE CARE
CHAPTER 27: PHARMACOTHERAPY RELATED TO WOMEN'S HEALTH
CHAPTER 28: PHARMACOTHERAPY RELATED TO MEN'S HEALTH
CHAPTER 29: PHARMACOTHERAPY RELATED TO TRANSGENDER CARE
CHAPTER 30: ANTIMICROBIAL PHARMACOTHERAPY
CHAPTER 31: ANTIRETROVIRAL PHARMACOTHERAPY
CHAPTER 32: PSYCHOPHARMACOLOGY AND INTEGRATIVE HEALTH
CHAPTER 33: PHARMACOTHERAPY FOR PAIN MANAGEMENT
CHAPTER 34: SUBSTANCE USE DISORDER
PART III: HEALTH PROMOTION AND MAINTENANCE
CHAPTER 35: OVER-THE-COUNTER MEDICATIONS
CHAPTER 36: PHARMACOTHERAPY FOR OBESITY
, CHAPTER 1: AN INTRODUCTION TO EVIDENCE-BASED CLINICAL
PRACTICE GUIDELINES
MULTIPLE CHOICE
1. What is the primary purpose of the nursing assessment?
1. Identifying underlying pathologic conditions
2. Assisting the physician in identifying medical conditions
3. Determining the patient's mental status
4. Exploring patient responses to health problems
ANS: 4
A nursing assessment is performed to identify the patient's response to health problems. During this
phase, a comprehensive information base is developed through physical examination, nursing history,
medical history, medication history, and professional observation. Identifying underlying pathologic
conditions and assisting the physician in identifying medical conditions is not part of the nursing process.
Determining the patient's mental status is only one component of the nursing assessment, not the
primary purpose.
FOR
ADVANCED PHARMACOLOGY FOR PRESCRIBERS,
1ST EDITION BY LUU, KAYINGO, AND HASS
COMPLETE CHAPTERS 1-36
MCQs WITH RATIONALIZED ANSWERS
,TABLE OF CONTENTS
PART I: FOUNDATIONS OF PHARMACOLOGY AND PRESCRIBING
CHAPTER 1: AN INTRODUCTION TO EVIDENCE-BASED CLINICAL
PRACTICE GUIDELINES
CHAPTER 2: PHARMACOKINETICS
CHAPTER 3: PHARMACODYNAMICS
CHAPTER 4: PHARMACOGENETICS AND PHARMACOGENOMICS
CHAPTER 5: PHARMACOLOGY ACROSS THE LIFE SPAN
CHAPTER 6: DRUG-THERAPY PRESCRIBING IN SPECIAL POPULATIONS
CHAPTER 7: DRUG DEVELOPMENT AND APPROVAL
CHAPTER 8: BASICS OF PRESCRIPTION WRITING
CHAPTER 9: RESPONSIBLE CONTROLLED-SUBSTANCE PRESCRIBING
CHAPTER 10: ANTIBIOTIC STEWARDSHIP
CHAPTER 11: APPLIED CALCULATIONS FOR PRESCRIBING
CHAPTER 12: PROMOTING ADHERENCE WITH PHARMACOTHERAPY
PART II: SYSTEM-SPECIFIC AND PATIENT-FOCUSED PRESCRIBING
CHAPTER 13: PHARMACOTHERAPY FOR EAR, NOSE, ORAL, AND THROAT
CONDITIONS
CHAPTER 14: PHARMACOTHERAPY FOR EYE CONDITIONS
CHAPTER 15: PHARMACOTHERAPY FOR SKIN CONDITIONS
CHAPTER 16: PHARMACOTHERAPY FOR NEUROLOGIC CONDITIONS
CHAPTER 17: PHARMACOTHERAPY FOR CARDIOVASCULAR CONDITIONS
, CHAPTER 18: PHARMACOTHERAPY FOR RESPIRATORY CONDITIONS
CHAPTER 19: PHARMACOTHERAPY FOR GASTROINTESTINAL CONDITIONS
CHAPTER 20: PHARMACOTHERAPY FOR GENITOURINARY CONDITIONS
CHAPTER 21: PHARMACOTHERAPY FOR RENAL, ACID-BASE, AND
FLUID/ELECTROLYTE DISORDERS
CHAPTER 22: PHARMACOTHERAPY FOR MUSCULOSKELETAL AND
RHEUMATOLOGIC CONDITIONS
CHAPTER 23: THERAPEUTIC APPLICATIONS OF IMMUNOLOGY AND VACCINES
CHAPTER 24: PHARMACOTHERAPY FOR ENDOCRINE DISORDERS
CHAPTER 25: PHARMACOTHERAPY FOR HEMATOLOGIC DISORDERS
CHAPTER 26: HEMATOLOGY/ONCOLOGY AND SUPPORTIVE CARE
CHAPTER 27: PHARMACOTHERAPY RELATED TO WOMEN'S HEALTH
CHAPTER 28: PHARMACOTHERAPY RELATED TO MEN'S HEALTH
CHAPTER 29: PHARMACOTHERAPY RELATED TO TRANSGENDER CARE
CHAPTER 30: ANTIMICROBIAL PHARMACOTHERAPY
CHAPTER 31: ANTIRETROVIRAL PHARMACOTHERAPY
CHAPTER 32: PSYCHOPHARMACOLOGY AND INTEGRATIVE HEALTH
CHAPTER 33: PHARMACOTHERAPY FOR PAIN MANAGEMENT
CHAPTER 34: SUBSTANCE USE DISORDER
PART III: HEALTH PROMOTION AND MAINTENANCE
CHAPTER 35: OVER-THE-COUNTER MEDICATIONS
CHAPTER 36: PHARMACOTHERAPY FOR OBESITY
, CHAPTER 1: AN INTRODUCTION TO EVIDENCE-BASED CLINICAL
PRACTICE GUIDELINES
MULTIPLE CHOICE
1. What is the primary purpose of the nursing assessment?
1. Identifying underlying pathologic conditions
2. Assisting the physician in identifying medical conditions
3. Determining the patient's mental status
4. Exploring patient responses to health problems
ANS: 4
A nursing assessment is performed to identify the patient's response to health problems. During this
phase, a comprehensive information base is developed through physical examination, nursing history,
medical history, medication history, and professional observation. Identifying underlying pathologic
conditions and assisting the physician in identifying medical conditions is not part of the nursing process.
Determining the patient's mental status is only one component of the nursing assessment, not the
primary purpose.
